New Delhi: Faster accessibility to the ground-breaking HIV drug lenacapavir in India will require waiver of local clinical trials, public health experts said. On Wednesday, half a dozen drug makers including three Indian companies entered into non-exclusive, royalty-free licensing agreements with the drug's developer, Gilead Sciences , to manufacture generic versions of lenacapavir and market it locally and in 120 low- and middle-income countries. The companies will have to apply for local clinical trial waiver to be able to supply the generic version of the drug which is touted as a game-changer in ending the HIV epidemic, experts said.
While Gilead has filed patents widely on the drug, the voluntary licence is meant to overcome patent barriers for sale in identified low- and middle-income countries. Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Basics of Generative AI : Unveiling Tomorrow's Innovations By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, Developer and Lead Instructor View Program Artificial Intelligence(AI) Master in Python Language Quickly Using .
